Syschem (India) Limited
SYSCHEM.BO
Bombay Stock Exchange43.35
INR
+0.68
- -
Syschem (India) Limited
SYSCHEM.BO
(Bombay Stock Exchange)
Recent
price
43.35
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Syschem (India) Limited, founded in 1984 and headquartered in Chandigarh, India, is a pharmaceutical company engaged in the manufacture of bulk drugs, active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, and contract manufacturing services. The company’s product portfolio includes a wide range of pharmaceutical formulations such as bulk drug intermediates and generic medicines, including but not limited to amoxicillin trihydrate, ampicillin trihydrate, cloxacillin sodium, dicloxacillin sodium, and flucloxacillin sodium. It also produces branded formulations like cough syrups, digestive enzymes, calcium supplements, iron supplements, protein tonics, and nutraceuticals, with brand names such as KUFKIL, SYSZYME, C-HEPRO T, MED-VIT, CALCIWIN, LYCOSYS, SYSFER, PRORICH, and LIVOSYS among others. Besides pharmaceutical products, Syschem caters to the herbal and personal care segment with specialized products like uterine tonics and hepatoprotective formulations. The company operates primarily within India but serves global markets through exports of its bulk drugs and specialty chemicals. It targets pharmaceutical manufacturers, contract manufacturing clients, and healthcare providers as core customers. Syschem is listed on the Bombay Stock Exchange (BSE) and has developed a reputation for product quality and regulatory compliance in the pharmaceutical sector. In the last 1-2 years, Syschem has notably improved its financial performance, registering a significant increase in net profits and sales, which indicates operational strengthening. The company has reduced debt levels substantially and approaches business growth through both organic expansion and strategic sales order acquisitions, including a recent order valued at approximately Rs. 1.84 crore for cefadroxil IP supply. In terms of corporate governance, recent key developments include re-appointment of directors, auditor appointments, and approval of related-party transactions in its 2025 Annual General Meeting. Furthermore, the company has progressed with capital structuring and participated in funding rounds with key shareholders consolidating equity positions. Overall, Syschem (India) Limited is a well-established pharmaceutical manufacturer focused on bulk drugs, intermediates, specialty chemicals, and contract manufacturing, reinforced by recent financial and operational improvements, strengthening its presence in both domestic and international pharmaceutical markets. Its diversified product offerings and sustained order flow underscore ongoing growth and strategic stability in the pharmaceutical industry landscape in India and abroad.